TheranosticTrials.org

Clinical Trial · NCT01654874

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Overview

This trial is a single-blind, cross-over design. Up to three patients with confirmed metastatic prostate adenocarcinoma and up to three healthy volunteers will receive two doses of 20.0 (± 3) mCi of intravenously administered 99mTc MIP 1404 (preparation A or preparation B). Whole-body planar scintigraphic images will be acquired at various time points on the day of study drug administration. A pelvic SPECT/CT image will be acquired on the day of study drug administration. Blood will be collected for pharmacokinetic measurements following study drug administration. Each participant will receive an initial study drug administration (preparation A) and a second study drug administration (preparation B) approximately 7 to 21 days later. A final follow-up visit will occur approximately 2 - 3 weeks after the second study drug administration.

Sponsor

Bivision Pharmaceuticals, Inc.

Phase

Phase 1

Contacts

Stanley J Goldsmith, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01654874

Drug / Compound

MIP-1404

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: SAAC

Eligibility

Inclusion

  • Hemoglobin and hematocrit within normal range
  • Karnofsky performance is ≥ 60Additional Inclusion Criteria for Healthy Volunteers:
  • Evidence of metastatic disease demonstrated by a documented abnormal bone scan, CT scan, or MRI
  • PSA laboratory assessment within normal range (PSA \< 4 ng/ml)
  • Participants must agree to use an acceptable form of birth control throughout the study period. Participants must agree to use condoms for a period of seven days after each study drug administration, if engaged in sexual activity.Additional Inclusion Criteria for Metastatic Prostate Adenocarcinoma Patients:
  • Histologic diagnosis of prostate cancer by validated medical history (pathology report, if available).
  • Normal findings on a digital rectal examination

Exclusion

  • Have received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants; or 12 months for 125I implants
  • Absolute neutrophil count (ANC) \< 2,000/mm3
  • Liver transaminases ≥ 1.5 x ULN
  • Total bilirubin ≥ 2.0 mg/dl
  • Have any medical condition or other circumstances which, in the opinion of the Investigator, would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations
  • Received a radioisotope within 5 physical half lives of that radioisotope prior to study enrollment
  • Have had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, in which the diagnosis and location have not been defined as clinically controlled or treated to complete response
  • Hematocrit \< 30% or hemoglobin \< 10 g/dlAdditional Exclusion Criteria for Metastatic Prostate Adenocarcinoma Patients:
  • Serum creatinine ≥ 2.0 mg/dl
  • Platelet count \< 100,000/mm3
  • Participant is determined by the Investigator to be clinically unsuitable for the study